Join to View Full Profile
5063 S Cottonwood StMurray, UT 84107
Phone+1 801-408-5155
Dr. Prendergast is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Emily Prendergast is an Obstetrics and Gynecology specialist with a subspecialty in Gynecologic Oncology, located in Murray, UT. She completed her medical education at the University of Arizona College of Medicine in 2010, followed by a residency at McGaw Medical Center of Northwestern University and a fellowship at UCLA. She is currently an Attending Physician in Gynecologic Oncology at both Intermountain Medical Center and LDS Hospital and has been with Abbott Northwestern Hospital since 2017. Her expertise includes chemotherapy, hereditary breast/ovarian cancer, gynecologic oncology, minimally invasive surgery, and clinical research. Dr. Prendergast has published several influential papers in her field, including studies on niraparib and rucaparib treatments, which are frequently cited by her peers.
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Gynecologic Oncology, 2014 - 2017
McGaw Medical Center of Northwestern UniversityResidency, Obstetrics and Gynecology, 2010 - 2014
University of Arizona College of MedicineClass of 2010
Certifications & Licensure
CA State Medical License 2014 - 2028
UT State Medical License 2022 - 2028
MN State Medical License 2017 - 2027
NV State Medical License 2024 - 2027
ID State Medical License 2024 - 2026
IL State Medical License 2013 - 2014
American Board of Obstetrics and Gynecology Obstetrics & Gynecology- American Board of Obstetrics and Gynecology Gynecologic Oncology
Publications & Presentations
PubMed
- 1 citationsThe combination of avutometinib and defactinib in treating recurrent low-grade serous ovarian cancer: a plain language summary of the Phase II clinical trial ENGOT-OV6...Susana N Banerjee, Els Van Nieuwenhuysen, Carol Aghajanian, Véronique D'Hondt, Bradley J Monk
Future Oncology. 2025-12-01 - 2 citationsClinical Evaluation of a Multi-Omic Diagnostic Model for Early-Stage Ovarian Cancer Detection.Robert A Law, Brendan M Giles, Rachel Culp-Hill, Enkhtuya Radnaa, Mattie Goldberg
Diagnostics. 2025-09-02 - 8 citationsEfficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201.Susana N Banerjee, Els Van Nieuwenhuysen, Carol Aghajanian, Véronique D'Hondt, Bradley J Monk
Journal of Clinical Oncology. 2025-09-01
Press Mentions
More Chemo May Not Equal Better Outcomes in Ovarian CaJanuary 16th, 2017- Hormone Replacement Therapy Improves Bone Mineral Loss After Salpingo-Oophorectomy for Ovarian CancerApril 11th, 2016
Guidelines for Bone Scans After Oophorectomy NeededSeptember 11th, 2017
Committees
- Member, SGO-Legislation and Regulation Committee 2017 - Present
Professional Memberships
- Member
- Member
- Member
- Society of Gynecologic OncologyMember
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
